Skeletal Dysplasia Market Is Likely To Boom With Robust Growth Rate In The Projected Period 2019-2025

Skeletal dysplasia is a heterogeneous category of heritable disorders that are characterized by abnormalities related to bone and cartilage growth. It results in disproportion of the head, spine, and long bones and abnormal size and shape of the skeleton. There could be other systems of the body involved in skeletal dysplasia, such as cardiac, respiratory, and neurologic systems. People with this disorder are typically of short stature. Skeletal dysplasia differs in etiopathogenetic mechanisms, inheritance patterns, prognoses, and natural histories. Some of the common types of skeletal dysplasia are hypochondroplasia, campomelic dysplasia, thanatophoric dysplasia, osteogenesis imperfecta, and achondroplasia.

In February 2019, Swedish researchers from Karolinska Institutet discovered a rare and relatively new skeletal disease that comes under the category of skeletal dysplasia. The study has been published in Nature Medicine, a peer-reviewed journal. According to the researchers, the molecular mechanism of the disease is surprisingly different. Small RNA molecules were observed to show a role that has not been found in any congenital human disease ever to date.

Get PDF template of this report: https://www.qyrconsulting.com/request-sample/4534

Key Players of the Global Skeletal Dysplasia Market

The report covers detailed analysis of leading companies operating in the global skeletal dysplasia market such as Dr. Reddy’s Laboratories, Celgene Corporation, Teva Pharmaceutical Industries, F. Hoffmann-La Roche AG, Merck Group, Abbott Laboratories, Eli Lilly and Company, Novartis AG, Regeneron Pharmaceutical, Inc., Cipla Inc., BioMarin Pharmaceutical Inc., and Clementia Pharmaceuticals.

Market Segmentation

By Disorder Type

● Hypophosphatasia

● Achondroplasia

By Treatment

● Medication

● Surgery

According to analysts, achondroplasia is predicted to account for a significant share of the global skeletal dysplasia market, considering its high prevalence and commonness. Among skeletal dysplasia treatments, medication is expected to show substantial growth in the global market because of high adoption of orphan drugs.

Read Report Overview: https://www.qyrconsulting.com/reports/global-skeletal-dysplasia-market

Contact US
QYR Consulting
17890 Castleton, Suite 218,
Los Angeles, CA – 91748
USA: +1 626 428 8800
China: +86 1082 945 717
Japan: +81 9038 009 273
India: +91 9766 478 224
Emails – sales@qyrconsulting.com
Web – https://www.qyrconsulting.com

About Us:
QYR Consulting established as a research firm in 2007 and have since grown into a trusted brand amongst many industries. Over the years, we have consistently worked toward delivering high-quality customized solutions for wide range of clients ranging from ICT to healthcare industries. With over 50,000 satisfied clients, spread over 80 countries, we have sincerely strived to deliver the best analytics through exhaustive research methodologies.

This release was published on openPR.